Details of the Drug

General Information of Drug (ID: DMKA2FL)

Drug Name
CD19/CD22 CAR T-Cells
Indication
Disease Entry ICD 11 Status REF
Acute lymphocytic leukaemia 2B33.3 Phase 1 [1]
B-cell lymphoma 2A86 Phase 1 [1]
B-cell prolymphocytic leukaemia 2A82.1 Phase 1 [1]
leukaemia 2A60-2B33 Phase 1 [1]
Non-hodgkin lymphoma 2B33.5 Phase 1 [1]
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
D03YEM
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell receptor CD22 (CD22) TTM6QSK CD22_HUMAN CAR-T-Cell-Therapy(Dual specific) [1]
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy(Dual specific) [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute lymphocytic leukaemia
ICD Disease Classification 2B33.3
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
B-cell receptor CD22 (CD22) DTT CD22 1.89E-11 -0.21 -0.58
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies